VALN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Valneva SE (VALN) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The stock is currently facing significant challenges, including legal investigations, a failed primary endpoint in its Phase 3 clinical trial, and bearish technical indicators. Analysts have downgraded the stock, and there are no strong positive catalysts to offset the risks. Given the investor's profile and the current market conditions, it is better to avoid this stock.
The stock is in a bearish trend with moving averages indicating downward momentum (SMA_200 > SMA_20 > SMA_5). The RSI of 18.278 suggests the stock is oversold, but this does not necessarily indicate a reversal. The MACD histogram is positive but contracting, showing weak momentum. Key support levels are at $5.335 and $5.036, with resistance at $6.305 and $6.605.
The Phase 3 clinical trial showed some positive results with 73.2% vaccine efficacy, and Jefferies sees potential for approval despite the trial's failure to meet the primary endpoint.
Legal investigation by Pomerantz LLP for potential securities fraud and unlawful business practices.
Phase 3 clinical trial failed to meet the primary endpoint, raising concerns about the Lyme disease vaccine's efficacy.
Significant stock price drop of 37.11% following trial results.
Goldman Sachs downgraded the stock to Sell with a $4.90 price target, citing uncertainty and a challenging outlook.
No financial data available for analysis.
Analysts are mixed but leaning negative. Goldman Sachs downgraded the stock to Sell with a $4.90 price target, citing uncertainty and challenges. Guggenheim lowered its price target to $11 from $13 but maintained a Buy rating. Jefferies reiterated a Buy rating with a $15 price target, viewing the stock's weakness as a buying opportunity despite the trial's failure to meet the primary endpoint.
